Safety, Tolerability, and Pharmacokinetics of EGT710, a Novel Coronavirus Mpro Inhibitor, in Healthy Adults: A Randomized, Single- and Multiple-Dose Study

IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Jart A. F. Oosterhaven, Jonathan Trolander, Lidiya Bebrevska, Hilmar Schiller, Begum Alaybeyoglu, Suzanne Gaudet, Allison Claas, Kamal Kumar Balavenkatraman, Renee Bergeron, Fernanda V. Duraes, Frederique Chaperon, Swati Ghanshani, Elisabete Goncalves, Steven J. Kovacs
{"title":"Safety, Tolerability, and Pharmacokinetics of EGT710, a Novel Coronavirus Mpro Inhibitor, in Healthy Adults: A Randomized, Single- and Multiple-Dose Study","authors":"Jart A. F. Oosterhaven,&nbsp;Jonathan Trolander,&nbsp;Lidiya Bebrevska,&nbsp;Hilmar Schiller,&nbsp;Begum Alaybeyoglu,&nbsp;Suzanne Gaudet,&nbsp;Allison Claas,&nbsp;Kamal Kumar Balavenkatraman,&nbsp;Renee Bergeron,&nbsp;Fernanda V. Duraes,&nbsp;Frederique Chaperon,&nbsp;Swati Ghanshani,&nbsp;Elisabete Goncalves,&nbsp;Steven J. Kovacs","doi":"10.1002/cpdd.70115","DOIUrl":null,"url":null,"abstract":"<p>Antiviral therapy is needed to address acute coronavirus disease. EGT710 is a novel low-molecular-weight inhibitor of the coronavirus main protease (M<sup>pro</sup>). This first-in-human study evaluated the safety, tolerability, and pharmacokinetics of EGT710 in healthy adults. The study conducted in the Netherlands involved three parts: a blinded, placebo-controlled, 3:1 randomized, single ascending dose Part A (n = 39); a multiple ascending dose Part B (n = 31); and an open-label, three-period, six sequence, randomized, cross-over Part C (n = 18) to evaluate food and formulation effects on EGT710 bioavailability. EGT710 was well tolerated. All adverse events (AEs) were mild (Grade 1), with no serious AEs or discontinuations. Aside from mild gastrointestinal AEs associated with EGT710, AE frequency was similar between groups with no dose-dependent or dose-limiting adverse effects. EGT710 was rapidly absorbed (median T<sub>max</sub> 2.0 h), showed sub-proportional AUC and C<sub>max</sub> increases and no significant accumulation with daily dosing. Bioavailability was comparable between suspension and capsule formulations. Food increased C<sub>max</sub> by 20% and AUC by 27%. EGT710 700 mg once daily for 7 days modestly induced CYP3A4 activity but had no effect on organic anion transporting polypeptide (OAT1/3) activity. Oral EGT710 (capsule and suspension) was safe and well tolerated, with pharmacokinetics that support further development as a treatment for coronavirus disease.</p>","PeriodicalId":10495,"journal":{"name":"Clinical Pharmacology in Drug Development","volume":"15 10","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cpdd.70115","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology in Drug Development","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpdd.70115","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Antiviral therapy is needed to address acute coronavirus disease. EGT710 is a novel low-molecular-weight inhibitor of the coronavirus main protease (Mpro). This first-in-human study evaluated the safety, tolerability, and pharmacokinetics of EGT710 in healthy adults. The study conducted in the Netherlands involved three parts: a blinded, placebo-controlled, 3:1 randomized, single ascending dose Part A (n = 39); a multiple ascending dose Part B (n = 31); and an open-label, three-period, six sequence, randomized, cross-over Part C (n = 18) to evaluate food and formulation effects on EGT710 bioavailability. EGT710 was well tolerated. All adverse events (AEs) were mild (Grade 1), with no serious AEs or discontinuations. Aside from mild gastrointestinal AEs associated with EGT710, AE frequency was similar between groups with no dose-dependent or dose-limiting adverse effects. EGT710 was rapidly absorbed (median Tmax 2.0 h), showed sub-proportional AUC and Cmax increases and no significant accumulation with daily dosing. Bioavailability was comparable between suspension and capsule formulations. Food increased Cmax by 20% and AUC by 27%. EGT710 700 mg once daily for 7 days modestly induced CYP3A4 activity but had no effect on organic anion transporting polypeptide (OAT1/3) activity. Oral EGT710 (capsule and suspension) was safe and well tolerated, with pharmacokinetics that support further development as a treatment for coronavirus disease.

Abstract Image

一种新型冠状病毒Mpro抑制剂EGT710在健康成人中的安全性、耐受性和药代动力学:一项随机、单剂量和多剂量研究
急性冠状病毒病需要抗病毒治疗。EGT710是新型冠状病毒主蛋白酶(Mpro)低分子量抑制剂。这项首次人体研究评估了EGT710在健康成人中的安全性、耐受性和药代动力学。在荷兰进行的这项研究包括三个部分:盲法、安慰剂对照、3:1随机、单次递增剂量的a部分(n = 39);多次递增剂量B部分(n = 31);C部分(n = 18)采用开放标签、三期、六序列、随机交叉试验,评估食品和制剂对EGT710生物利用度的影响。EGT710耐受性良好。所有不良事件(ae)均为轻度(1级),无严重ae或停药。除了与EGT710相关的轻度胃肠道不良反应外,AE频率在没有剂量依赖性或剂量限制性不良反应的组之间相似。EGT710吸收迅速(中位Tmax 2.0 h), AUC和Cmax呈亚比例增加,且每日给药无显著积累。悬浮液和胶囊制剂的生物利用度相当。食物增加20% Cmax和27% AUC。EGT710 700 mg每日1次,连续7 d,适度诱导CYP3A4活性,但对有机阴离子转运多肽(OAT1/3)活性无影响。口服EGT710(胶囊和混悬液)安全且耐受性良好,其药代动力学支持进一步开发作为冠状病毒疾病的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
10.00%
发文量
154
期刊介绍: Clinical Pharmacology in Drug Development is an international, peer-reviewed, online publication focused on publishing high-quality clinical pharmacology studies in drug development which are primarily (but not exclusively) performed in early development phases in healthy subjects.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书